SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-188992
Filing Date
2022-07-07
Accepted
2022-07-07 07:06:03
Documents
12
Period of Report
2022-07-05
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d355522d8k.htm   iXBRL 8-K 28851
  Complete submission text file 0001193125-22-188992.txt   154805

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA verv-20220705.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20220705_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20220705_pre.xml EX-101.PRE 11707
6 EXTRACTED XBRL INSTANCE DOCUMENT d355522d8k_htm.xml XML 3473
Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 221070630
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences